A Phase 3 interventional study of Certoparin in Renal Dialysis, sponsored by Novartis. Completed at 9 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-07-10.
Sponsored by Novartis · Phase 3, Interventional, and Prevention
This study will assess the efficacy, safety and pharmacokinetics of certoparin when used to prevent clotting during hemodialysis.
Novartis is the lead sponsor of 703 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Certoparin
Certoparin
Number of patients requiring uptitration
Time frame: Week 8
Pharmacokinetics of Certoparin
Time frame: Day 1, Week 4
Safety and tolerability of Certoparin
Time frame: 8 weeks
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis